Dashboard
Manage Tickers

GILDGILEAD SCIENCES, INC.

Nasdaq gilead.com


$ 68.61 $ -0.22 (-0.32 %)    

Friday, 28-Jun-2024 15:59:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 479.98 $ -3.41 (-0.71 %)
DIA $ 391.11 $ -0.45 (-0.11 %)
SPY $ 544.70 $ -1.67 (-0.31 %)
TLT $ 91.77 $ -1.75 (-1.87 %)
GLD $ 215.03 $ 0.04 (0.02 %)
$ 68.61
$ 68.82
$ 0.00 x 0
$ 0.00 x 0
$ 68.07 - $ 68.99
$ 61.32 - $ 85.92
7,176,254
na
85.83B
$ 0.33
$ 176.97
TBD
na
na ($ 0.04)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2024 03-31-2024 10-Q
2 02-23-2024 12-31-2023 10-K
3 11-07-2023 09-30-2023 10-Q
4 08-04-2023 06-30-2023 10-Q
5 05-03-2023 03-31-2023 10-Q
6 02-22-2023 12-31-2022 10-K
7 11-02-2022 09-30-2022 10-Q
8 08-08-2022 06-30-2022 10-Q
9 05-04-2022 03-31-2022 10-Q
10 02-23-2022 12-31-2021 10-K
11 11-03-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 02-25-2021 12-31-2020 10-K
15 11-04-2020 09-30-2020 10-Q
16 08-06-2020 06-30-2020 10-Q
17 05-06-2020 03-31-2020 10-Q
18 02-25-2020 12-31-2019 10-K
19 11-05-2019 09-30-2019 10-Q
20 08-06-2019 06-30-2019 10-Q
21 05-08-2019 03-31-2019 10-Q
22 02-26-2019 12-31-2018 10-K
23 11-06-2018 09-30-2018 10-Q
24 08-06-2018 06-30-2018 10-Q
25 05-09-2018 03-31-2018 10-Q
26 02-27-2018 12-31-2017 10-K
27 11-07-2017 09-30-2017 10-Q
28 08-07-2017 06-30-2017 10-Q
29 05-10-2017 03-31-2017 10-Q
30 02-27-2017 12-31-2016 10-K
31 11-07-2016 09-30-2016 10-Q
32 08-05-2016 06-30-2016 10-Q
33 05-06-2016 03-31-2016 10-Q
34 02-24-2016 12-31-2015 10-K
35 11-04-2015 09-30-2015 10-Q
36 08-05-2015 06-30-2015 10-Q
37 05-08-2015 03-31-2015 10-Q
38 02-25-2015 12-31-2014 10-K
39 11-05-2014 09-30-2014 10-Q
40 08-04-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

wall-streets-most-accurate-analysts-give-their-take-on-3-health-care-stocks-with-over-3-dividend-yields
Wall Street's Most Accurate Analysts Give ...
06/28/2024 11:30:58

gilead-sciences-canada-announces-phase-3-purpose-1-trial-results-lenacapavir-shows-100-efficacy-in-hiv-prevention-for-cisgender-women-data-monitoring-committee-recommends-offering-open-label-lenacapavir-to-all-participants
Gilead Sciences Canada Announces Phase 3 P...
06/26/2024 12:34:09

– First Phase 3 HIV Prevention Trial to Show Zero Infections –– Independent Data Monitoring Committee Recommended That Gilead S...

10-health-care-stocks-whale-activity-in-todays-session
10 Health Care Stocks Whale Activity In To...
06/25/2024 17:35:24

Core News & Articles
CNBC Halftime Report Final Trades: Keurig ...
06/25/2024 17:01:09

gilead-sciencess-options-frenzy-what-you-need-to-know
Gilead Sciences's Options Frenzy: What You...
06/24/2024 15:46:28

draftkings-and-dell-were-among-the-10-biggest-large-cap-stock-gainers-last-week-june-16-june-22-are-these-in-your-portfolio
DraftKings And Dell Were Among The 10 Bigg...
06/23/2024 15:43:40

Top performers last week were SRPT (+29.50%), SIRI (+16.73%), TOST (+15.57%), GILD (+12.62%), CHWY (+10.59%), ACN (+9.80%), DKN...

nvidia-snaps-8-week-winning-run-sp-500-marks-longest-streak-without-a-2-drop-since-great-recession-oil-prices-stage-comeback-this-week-in-the-market
Nvidia Snaps 8-Week Winning Run, S&P 500 M...
06/21/2024 20:18:50

Stock market rally continues with new highs in S&P 500 and Nasdaq 100, driven by tech and semiconductor sectors, but concer...

gilead-sciences-faces-wall-street-speculation-about-obesity-drugs-despite-focus-on-liver-treatments
Gilead Sciences Faces Wall Street Speculat...
06/21/2024 15:42:22

Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatme...

why-gilead-sciences-stock-is-trading-higher-friday
Why Gilead Sciences Stock Is Trading Highe...
06/21/2024 15:36:20

On Thursday before the market opened, Gilead announced efficacy data for its possible HIV prevention drug, Lenacapavir.

Core News & Articles
Benzinga Market Summary: Housing Starts Co...
06/20/2024 19:58:33

sp-500-nasdaq-100-dip-from-record-highs-as-investors-take-chipmaker-profits-energy-sector-rebounds-yields-rise-whats-driving-markets-thursday
S&P 500, Nasdaq 100 Dip From Record Highs ...
06/20/2024 17:41:02

After the Juneteenth holiday break, Wall Street reopened with a cautious tone, as the S&P 500 and Nasdaq 100 indices declin...

baird-maintains-neutral-on-gilead-sciences-maintains-80-price-target
Baird Maintains Neutral on Gilead Sciences...
06/20/2024 17:38:27

Baird analyst Brian Skorney maintains Gilead Sciences (NASDAQ:GILD) with a Neutral and maintains $80 price target.

why-is-gilead-sciences-stock-trading-higher-on-thursday
Why Is Gilead Sciences Stock Trading Highe...
06/20/2024 16:00:38

Gilead Sciences announced its Phase 3 PURPOSE 1 trial results showing 100% efficacy of twice-yearly injectable lenacapavir in p...

Core News & Articles
Benzinga Market Summary: AMD Rises, Jobles...
06/20/2024 15:53:35

kb-home-reports-upbeat-earnings-joins-harrow-accenture-gilead-sciences-and-other-big-stocks-moving-higher-on-thursday
KB Home Reports Upbeat Earnings, Joins Har...
06/20/2024 14:21:23

gilead-announces-results-from-interim-analysis-of-phase-3-trial-lenacapavir-showed-100-efficacy-for-hiv-prevention-shows-superiority-to-daily-truvada
Gilead Announces Results From Interim Anal...
06/20/2024 12:49:00

-Bloomberg

100-invested-in-this-stock-20-years-ago-would-be-worth-800-today
$100 Invested In This Stock 20 Years Ago W...
06/19/2024 18:30:19

detailed-data-from-gilead-halted-blood-cancer-drug-magrolimab-program-shows-higher-deaths-and-side-effects
Detailed Data From Gilead Halted Blood Can...
06/17/2024 16:19:51

Gilead's recent data from two Phase 3 trials show higher adverse events and lower transplant rates in patients treated with...

what-8-analyst-ratings-have-to-say-about-gilead-sciences
What 8 Analyst Ratings Have To Say About G...
06/14/2024 16:00:50

rbc-capital-reiterates-sector-perform-on-gilead-sciences-maintains-74-price-target
RBC Capital Reiterates Sector Perform on G...
06/14/2024 13:58:11

RBC Capital analyst Brian Abrahams reiterates Gilead Sciences (NASDAQ:GILD) with a Sector Perform and maintains $74 price ta...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

06/28/2024 Malibu Boats, Inc. (MBUU)
07/01/2024 Globe Life Inc. f/k/a Torchmark Corporation (GL)
07/01/2024 Equinix, Inc. (EQIX)
07/02/2024 Intel Corporation (INTC)
07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)